latest news.
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days Competitive Generic Therapy (CGT) exclusivity
us.
Together, everyone at Cosette contributes to a culture that fosters innovation, celebrates collaboration and recognizes excellence. We are perpetually pursuing the highest quality standards, the most efficient supply chain and innovating every day in everything we do.
leadership.
Our highly experienced leadership team is busy writing the next, most ambitious chapter of our story. Building on a 100+ year heritage, their shared vision of innovation will leverage our expertise, efficiency, and infrastructure to create remarkable new opportunities.
products.
While staying true to our proud therapeutic history of dermatology products, suppositories, and oral liquids, we’re busy expanding our offerings – through strategic partnerships and internal R&D. Our focus on innovation and supply reliability is the foundation of our rapidly diversifying portfolio.
we care.
Cosette is committed to understanding patients’ unique health journeys so we can anticipate their needs and help achieve their goals.
newsroom.
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days Competitive Generic Therapy (CGT) exclusivity
Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced…
Termination of Proposed Acquisition of Mayne Pharma
Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company,…
Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs
Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced…
